Subscribe
Core coverageDYN

Company profile / DYN

Dyne Therapeutics

Clinaptis stanceNeutral
ConvictionMedium
Ticker
DYN
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 9, 2026
Genetic Medicine / Neuromuscular

Clinical-stage genetic-medicine company developing targeted oligonucleotide therapies for neuromuscular diseases through its transferrin-receptor-1-directed FORCE platform. Its two lead programs are z-rostudirsen, under FDA Priority Review for Duchenne muscular dystrophy amenable to exon 51 skipping, and z-basivarsen, in registrational development for myotonic dystrophy type 1.

01 / Clinaptis view

The current read

Neutral, with medium conviction: clinically credible, but the price already credits both programs. Dyne has shown what most muscle-delivery platforms have not: high target engagement plus directionally consistent functional signals.

  1. In exon-51 DMD, z-rostudirsen produced 5.46% muscle-content-adjusted dystrophin at six months (p<0.0001), or 2.87% unadjusted. Improvement relative to placebo was seen across all six prespecified functional measures, and FVC% predicted remained stable while placebo declined.
  2. The functional evidence is weaker than the headline suggests: the 32-patient registrational cohort (24 active, eight placebo) was compared with a pooled DELIVER placebo group, and the two nominal p<0.05 results were post hoc because the prespecified plan had no formal functional testing. The January 21, 2027 PDUFA is therefore an accelerated-approval judgment on dystrophin as a surrogate, with function supportive rather than confirmatory.
  3. FORZETTO, an approximately 90-patient Phase 3 trial in ambulatory boys, is the confirmatory test. DM1 is the larger platform question, and it just became harder: on September 8, Novartis’ del-desiran missed its vHOT primary endpoint in the 159-patient Phase 3 HARBOR trial without disclosing an effect size.
  4. HARBOR does not invalidate splicing correction or establish that z-basivarsen fails, but vHOT is also the early clinical-benefit indicator in its proposed accelerated-approval package, so the bridge weakens and scrutiny is likely to rise. We put the chance of a statistical win in the ACHIEVE registrational cohort at 38–51%, about 41%, with topline in Q1 2027 and a potential BLA submission in Q3 2027.
  5. The balance sheet is not a near-term constraint, with estimated liquidity of $1.12–1.15 billion at September 30 against $211 million of adjusted debt. At the October 6 close of $15.40 and 191.14 million fully diluted shares, enterprise value is about $2.0 billion.
  6. After $611 million for DMD and $250 million for FSHD and the platform, the price still attributes about $1.5 billion to DM1, 37% of our $4.0 billion unrisked NPV. At roughly 41% odds, with a miss worth nothing, a win must retain about 91% of that value to justify the price, so we make no directional call on the readout.
02 / Consensus gap

Where the market may differ

The bullish framing treats DYN as a two-asset late-stage company with FORCE already validated by delivery, dystrophin production, splicing correction and early functional signals. Priority Review and two ongoing confirmatory Phase 3 trials support that view.

  1. The gap is that regulatory progress is not clinical validation. The DMD filing rests on a 32-patient cohort and a surrogate endpoint; its statistically tested functional comparisons were post hoc and used pooled controls.
  2. In DM1, the accelerated-approval case rests on CASI-22 splicing correction supported by function, including vHOT, in a 71-patient registrational cohort. HARBOR’s failure does not read directly across to a different molecule, delivery construct or dose.
  3. It does, however, give FDA a completed, well-powered dataset in which the proposed early clinical-benefit bridge did not separate, raising the burden on Dyne to show that z-basivarsen’s splicing correction comes with a coherent clinical signal. The market could overcorrect: HARMONIA uses five-times sit-to-stand at Week 49 as its primary endpoint, not vHOT, and tests several functional domains.
  4. Our 38–51% odds count any statistical win, yet at roughly 2.0–2.6 seconds the confidence interval could still include a 1-second effect. If ACHIEVE instead shows myotonia improvement alongside credible strength and mobility trends, the accelerated-approval path remains open; the decisive question is whether FORCE converts delivery into measurable function under randomized, prespecified conditions.
  5. So far Dyne has shown that biomarkers move, and that function moves in analyses that do not yet meet that standard. The January PDUFA is the first test of how FDA weighs the gap.
Coverage state
Standard profile
What the review turns on
Key variable

Whether FORCE-mediated biomarker activity translates into reproducible, prespecified functional benefit—and whether FDA accepts the current surrogate-plus-supportive-evidence packages before Phase 3 confirms that translation

Next catalyst

Z-rostudirsen · FDA PDUFA decision · Jan 21, 2027; Z-basivarsen · ACHIEVE registrational-cohort topline · Q1 2027; Z-basivarsen · DM1 BLA submission, if filed · Q3 2027; Read-through: PepGen FREEDOM2 10 mg/kg cohort · Nov 2026; Read-through: Sarepta AMONDYS 45 / VYONDYS 53 FDA decisions · Feb 28, 2027

03 / Pipeline

Key programs

4 assets · 4 programs

AssetIndicationStageNext event
Zeleciment rostudirsen (z-rostudirsen; DYNE-251)
Duchenne muscular dystrophy amenable to exon 51 skipping
BLA under Priority Review / confirmatory Phase 3
FDA PDUFA decision · Jan 21, 2027Sets DMD value ($914M approval case vs $50M after a complete response letter in our bridge) and resets the price-implied DM1 residual; Sarepta's Feb 28, 2027 exon-skipping decisions are a limited read-through
Zeleciment basivarsen (z-basivarsen; DYNE-101)
Myotonic dystrophy type 1
Phase 1/2 registrational cohort / confirmatory Phase 3
ACHIEVE REC topline · Q1 2027vHOT effect size and 95% CI, observed noise and robustness of a statistical win; we estimate roughly 41% odds of a statistical win
DYNE-302
Facioscapulohumeral muscular dystrophy
IND-cleared
First-in-human development timing not yet confirmed
DYNE-401
Pompe disease
Preclinical
IND-enabling development
04 / Connected research

Published on DYN

View full archive
  1. 01

    Dyne (DYN): HARBOR Cut the Price. Didn’t Lower the Bar for ACHIEVE-REC DM1

    Novartis Phase 3 HARBOR miss hit Dyne’s valuation though we estimate $1.5B NPV is still attributable to DM1. We remain cautious (41% odds) into Q1 2027 Achieve-REC readout of Z-basivarsen.

    Read